Appointment of CEO and Managing Director
Filed with ASX · · 2 pages · English
Proteomics International Laboratories Ltd (Proteomics International or the Company; ASX: PIQ) is pleased to announce the appointment of David Morris as Chief Executive Officer (CEO) and Managing Director (MD). Mr Morris will assume full operational and strategic responsibilities effective 19 January 2026. David is a global healthcare and medical technology executive with extensive experience spann
Proteomics International Laboratories Ltd. on 6ix
Earlier from Proteomics International Laboratories
- Proteomics US lab CAP accredited - extends precision Dx lab
- US patent secured for PromarkerEso diagnostic test for EAC
- PromarkerD predicts risk of DKD in Aboriginal Australians
- Response to ASX Price Query
- US Medicare sets reimbursement price for PromarkerD DKD test
Later from Proteomics International Laboratories
- Canadian patent secured for PromarkerEso test for EAC
- Quarterly Activities/Appendix 4C Cash Flow Report
- Appendix 4D and Interim Financial Report
- Restructure, Executive Appointment and Board Update
- Proteomics Strategic Plan
Follow Proteomics International Laboratories into a list and get an email when it puts out news.
Follow Proteomics International Laboratories